Claims for Patent: 8,691,225

Summary for Patent: 8,691,225

Title:	Antibodies against the ectodomain of ErbB3 and uses thereof
Abstract:	The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
Inventor(s):	Schoeberl; Birgit (Cambridge, MA), Nielsen; Ulrik (Quincy, MA), Feldhaus; Michael (Grantham, NH), Muruganandam; Arumugam (Bangalore, IN), Buckler; David (Chester, NJ)
Assignee:	Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	12/545,279
Patent Claims:	1. A method of treating an ErbB3-expressing cancer in a human subject, said method comprising administering to the subject a therapeutically effective amount of a monoclonal antibody or antigen binding portion thereof that binds to human ErbB3 and that comprises a heavy chain variable region CDR1 comprising SEQ ID NO:7, a heavy chain variable region CDR2 comprising SEQ ID NO:8, a heavy chain variable region CDR3 comprising SEQ ID NO:9, a light chain variable region CDR1 comprising SEQ ID NO:10, a light chain variable region CDR2 comprising SEQ ID NO:11 and a light chain variable region CDR3 comprising SEQ ID NO:12. 2. The method of claim 1, wherein the monoclonal antibody or the antigen binding portion thereof is administered in combination with a therapeutically effective amount of a second agent, which is an anti-cancer agent other than the monoclonal antibody or the antigen binding portion thereof. 3. The method of claim 2 wherein the second agent comprises a second antibody or antigen binding portion thereof. 4. The method of claim 2 wherein the second agent is selected from: a protein synthesis inhibitor, a somatostatin analogue, an immunotherapeutic agent, and an enzyme inhibitor. 5. The method of claim 2 wherein the second agent is selected from: a small molecule targeting IGF1R, a small molecule targeting EGFR, a small molecule targeting ErbB2, a small molecule targeting cMET, an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule targeting agent, a kinase inhibitor, a hormonal therapy, a glucocorticoid, an aromatase inhibitor, an mTOR inhibitor, and a chemotherapeutic agent. 6. The method of claim 2 wherein the second agent is panitumumab, trastuzumab or cetuximab. 7. The method of claim 5 wherein the second agent is paclitaxel. 8. The method of claim 5 wherein the second agent is cisplatin. 9. The method of claim 5 wherein the second agent is erlotinib or lapatinib. 10. The method of claim 1, wherein the antibody is a human antibody, a humanized antibody, a bispecific antibody, or a chimeric antibody. 11. The method of claim 1, wherein the antigen binding portion is a portion of a human antibody, a humanized antibody, or a chimeric antibody. 12. The method of claim 1, wherein the antigen binding portion is selected from the group consisting of a Fab, a Fab'2, and an scFv. 13. The method of claim 1, wherein the antibody is of an isotype is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgAsec, an IgD, and an IgE. 14. The method of claim 1, wherein the antibody or the antigen binding portion thereof inhibits betacellulin, heregulin, or TGF.alpha.-mediated phosphorylation of ErbB3 in AdrR cells. 15. The method of claim 1, wherein the antibody or the antigen binding portion thereof comprises a heavy chain variable region comprising SEQ ID NO:1 and a light chain variable region comprising SEQ ID NO:2. 16. The method of claim 5, wherein the kinase inhibitor is a tyrosine kinase inhibitor, a protein kinase B inhibitor, a phosphatidylinositol 3-kinase inhibitor, a cyclin dependent kinase inhibitor, or an MEK inhibitor. 17. The method of claim 1, wherein the antibody or the antigen binding portion thereof is administered parenterally. 18. The method of claim 1, wherein the antibody or the antigen binding portion thereof is contained in a pharmaceutical composition formulated with a pharmaceutically acceptable carrier. 19. The method of claim 18, wherein the pharmaceutical composition is in dosage unit form. 20. The method of claim 1, wherein the ErbB3-expressing cancer is a tumor selected from the group consisting of ovarian cancer, pancreatic cancer, renal cancer, prostate cancer, lung cancer, melanoma cancer and breast cancer.

Details for Patent 8,691,225

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-02-16
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-02-16
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2027-02-16
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2027-02-16
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2027-02-16
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-02-16